Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Year: 2023
Type: supplementary-materials
Abstract: Treatment-related adverse events in treated patients with MET amplification and/or MET IHC 2+/3+
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4366523908